U.S. Medical Device Maker Edwards Lifesciences' Patent Practices And Policy Against What It Says Are Copycat Devices Triggered EU Antitrust Regulators' Dawn Raids Last Month, A Person Familiar With The Matter Said.
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences' patent practices and policy against what it says are copycat devices triggered EU antitrust regulators' dawn raids last month.
October 17, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Edwards Lifesciences' patent practices and policy against what it says are copycat devices triggered EU antitrust regulators' dawn raids last month, which could potentially lead to legal and regulatory issues for the company.
The news of the EU antitrust regulators' dawn raids on Edwards Lifesciences due to its patent practices and policy against alleged copycat devices could potentially lead to legal and regulatory issues for the company. This could negatively impact the company's reputation and financial performance, which could in turn negatively affect its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100